English Polski

Wyszuk. zaawans.

Tom 12, Nr 1 (2017)
Artykuł przeglądowy
Opublikowany online: 2017-01-29

dostęp otwarty

Pokaż PDF Pobierz plik PDF
Wyświetlenia strony 1663
Wyświetlenia/pobrania artykułu 4236
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Dyslipidemia aterogenna w codziennej praktyce — interdyscyplinarny konsensus polskich ekspertów

Filip Szymański, Krzysztof J. Filipiak, Beata Wożakowska-Kapłon, Jacek P. Szaflik, Grzegorz Dzida, Iwona Kurkowska-Jastrzębska, Krzysztof Narkiewicz, Monika Łazicka-Gałecka, Robert J. Gil, Janusz Gumprecht
DOI: 10.5603/FC.a2016.0106
Folia Cardiologica 2017;12(1):33-49.

Streszczenie

Zaburzenia lipidowe są najbardziej rozpowszechnionym czynnikiem ryzyka chorób układu sercowo-naczyniowego w Polsce. Według najnowszych wytycznych towarzystw naukowych nadrzędnym celem terapii hipolipemizującej jest obniżenie stężenia cholesterolu frakcji LDL, niemniej jednak nie można nie doceniać wpływu, jaki na postęp zmian miażdżycowych w naczyniach tętniczych wywiera aterogenna dyslipidemia, czyli podwyższone stężenie triglicerydów (TG) i lipoprotein o bardzo małej gęstości (VLDL) zawierających TG oraz obniżone stężenie frakcji cholesterolu HDL (HDL-C). Wysokie stężenie TG i niskie stężenie HDL-C są niezależnymi czynnikami ryzyka zdarzeń sercowo-naczyniowych, które można skutecznie kontrolować i leczyć za pomocą statyn i fenofibratu. Poniższe stanowisko polskich ekspertów wielu dziedzin stanowi próbę podsumowania najnowszej wiedzy w dziedzinie dyslipidemii aterogennej i sformułowanie zaleceń dotyczących jej leczenia.

Słowa kluczowe: aterogenna dyslipidemiastanowisko ekspertówryzyko sercowo-naczyniowe

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Catapano AL, Graham I, De Backer G. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016; 253: 281–344.
    CrossRefPubMed
  2. Piepoli MF, Hoes AW, Agewall S, et al. Authors/Task Force Members:, Authors/Task Force Members, Additional Contributor: Simone Binno (Italy), Document Reviewers:, Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29): 2315–2381.
    CrossRefPubMed
  3. Leiter LA, Lundman P, da Silva PM, et al. DYSIS investigators. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med. 2011; 28(11): 1343–1351.
    CrossRefPubMed
  4. Zdrojewski T, Solnica B, Cybulska B, et al. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol. 2016; 74(3): 213–223.
    CrossRefPubMed
  5. de la Sierra A, Gorostidi M, Aranda P, et al. Prevalence of Atherogenic Dyslipidemia in Spanish Hypertensive Patients and Its Relationship With Blood Pressure Control and Silent Organ Damage. Rev Esp Cardiol (Engl Ed). 2015; 68(7): 592–598.
    CrossRefPubMed
  6. Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013; 7(5): 484–525.
    CrossRefPubMed
  7. Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009; 53(4): 316–322.
    CrossRefPubMed
  8. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012; 307(12): 1302–1309.
    CrossRefPubMed
  9. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996; 3(2): 213–219.
    PubMed
  10. Faergeman O, Holme I, Fayyad R, et al. Steering Committees of IDEAL and TNT Trials. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009; 104(4): 459–463.
    CrossRefPubMed
  11. Miller M, Cannon CP, Murphy SA, et al. PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008; 51(7): 724–730.
    CrossRefPubMed
  12. Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J. 1998; 19 Suppl A: A2–11.
    PubMed
  13. Barter P, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007; 357(13): 1301–1310.
    CrossRefPubMed
  14. Retnakaran R, Cull CA, Thorne KI, et al. UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006; 55(6): 1832–1839.
    CrossRefPubMed
  15. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435): 685–696.
    CrossRefPubMed
  16. Buse JB, Bigger JT, Byington RP. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007; 99(12A): 21i–31i.
    CrossRefPubMed
  17. Ginsberg HN, Elam MB, Lovato LC, et al. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17): 1563–1574.
    CrossRefPubMed
  18. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation. 2000; 102(1): 21–27.
    CrossRef
  19. Arbel Y, Klempfner R, Erez A, et al. BIP Study Group. Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. Cardiovasc Diabetol. 2016; 15: 11.
    CrossRefPubMed
  20. Lyons TJ, Jenkins AJ, Zheng D. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004; 45(3): 910–918.
    PubMed
  21. Keech A, Simes RJ, Barter P, et al. FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) Lancet. 2005; 366: 1840–1861.
  22. Ansquer JC, Foucher C, Rattier S, et al. DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005; 45(3): 485–493.
    CrossRefPubMed
  23. Chew EY, Ambrosius WT, Davis MD, et al. ACCORD Study Group, ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010; 363(3): 233–244.
    CrossRefPubMed
  24. Catapano AL, Graham I, De Backer B, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2016; 37(39): 2999–3058.
    CrossRef
  25. Wożakowska-Kapłon B, Filipiak KJ, Mamcarz A, et al. [Actual problems of dyslipidaemia treatment in Poland - 2nd Declaration of Sopot. Experts' Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy]. Kardiol Pol. 2014; 72(9): 847–853.
    CrossRefPubMed
  26. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372(25): 2387–2397.
    CrossRefPubMed
  27. Miller M, Cannon CP, Murphy SA, et al. PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008; 51(7): 724–730.
    CrossRefPubMed
  28. Yun KHo, Shin IS, Rhee SJ, et al. Clinical significance of on-treatment triglyceride level in patients treated by percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. Korean J Intern Med. 2009; 24(4): 330–336.
    CrossRefPubMed
  29. Schwartz GG, Abt M, Bao W, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015; 65(21): 2267–2275.
    CrossRefPubMed
  30. Buturak A, Degirmencioglu A, Erturk M, et al. Impact of increased admission lipid levels on periprocedural myocardial injury following an elective percutaneous coronary intervention. Coron Artery Dis. 2015; 26(4): 333–340.
    CrossRefPubMed
  31. Shah HD, Parikh KH, Chag MC, et al. Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. Exp Clin Cardiol. 2007; 12(2): 91–96.
    PubMed
  32. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet. 2008; 371(9607): 117–125.
    CrossRef
  33. Fruchart JC, Sacks FM, Hermans MP, et al. Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008; 5(4): 319–335.
    CrossRefPubMed
  34. Guy J, Ogden L, Wadwa RP, et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. Diabetes Care. 2009; 32(3): 416–420.
    CrossRefPubMed
  35. Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009; 53(4): 316–322.
    CrossRefPubMed
  36. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010; 375(9729): 1875–1884.
    CrossRefPubMed
  37. Jun M, Zhu B, Tonelli M, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012; 60(20): 2061–2071.
    CrossRefPubMed
  38. Ginsberg HN, Elam MB, Lovato LC, et al. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17): 1563–1574.
    CrossRefPubMed
  39. Mychaleckyj JC, Craven T, Nayak U, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care. 2012; 35(5): 1008–1014.
    CrossRefPubMed
  40. Ting RD, Keech AC, Drury PL, et al. FIELD Study Investigators. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care. 2012; 35(2): 218–225.
    CrossRefPubMed
  41. Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011; 54(2): 280–290.
    CrossRefPubMed
  42. Udani SM, Bakris GL. Do fibrates truly preserve kidney function? Nat Rev Endocrinol. 2011; 7(3): 130–131.
    CrossRefPubMed
  43. Niewada M, Skowrońska M, Ryglewicz D, et al. Polish National Stroke Prevention and Treatment Collaborative Group. Acute ischemic stroke care and outcome in centers participating in the Polish National Stroke Prevention and Treatment Registry. Stroke. 2006; 37(7): 1837–1843.
    CrossRefPubMed
  44. Sacco RL, Benjamin EJ, Broderick JP, et al. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke. 1997; 28(7): 1507–1517.
    PubMed
  45. González-García S, González-Quevedo A, Fernández-Concepción O, et al. Gonzales-Quevedo Monteagudo A, Zuaznabar MAB. Association between blodd lipids and types of strokes. MEDICC Review. 2008; 10: 27–32.
  46. Iso H, Jacobs DR, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989; 320(14): 904–910.
    CrossRefPubMed
  47. Collins R, Armitage J, Parish S, et al. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004; 363(9411): 757–767.
    CrossRefPubMed
  48. Amarenco P, Bogousslavsky J, Callahan A, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355(6): 549–559.
    CrossRefPubMed
  49. Amarenco P, Labreuche J, Lavallée P, et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004; 35(12): 2902–2909.
    CrossRefPubMed
  50. O'Donnell MJ, Chin SL, Rangarajan S, et al. INTERSTROKE investigators, INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010; 376(9735): 112–123.
    CrossRefPubMed
  51. Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA. 2001; 285(21): 2729–2735.
    PubMed
  52. Pikula A, Beiser AS, Wang J, et al. Lipid and lipoprotein measurements and the risk of ischemic vascular events: Framingham Study. Neurology. 2015; 84(5): 472–479.
    CrossRefPubMed
  53. Zhu S, Su G, Meng QH. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clin Chem. 2006; 52(11): 2036–2042.
    CrossRefPubMed
  54. Schwartz GG, Abt M, Bao W, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015; 65(21): 2267–2275.
    CrossRefPubMed
  55. Alpérovitch A, Kurth T, Bertrand M, et al. Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study. BMJ. 2015; 350: h2335.
    PubMed
  56. Ouk T, Gautier S, Pétrault M, et al. Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemia. J Cereb Blood Flow Metab. 2014; 34(3): 542–551.
    CrossRefPubMed
  57. Zhou YH, Ye XF, Yu FF, et al. Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention. BMC Neurol. 2013; 13: 1.
    CrossRefPubMed
  58. Wang D, Liu B, Tao W, et al. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev. 2015(10): CD009580.
    CrossRefPubMed
  59. Davis TME, Yeap BB, Davis WA, et al. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2008; 51(4): 562–566.
    CrossRefPubMed
  60. Cho YeR, Lim JiH, Kim MY, et al. Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice. PLoS One. 2014; 9(1): e83204.
    CrossRefPubMed
  61. Othman A, Benghozi R, Alecu I, et al. Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy? J Clin Lipidol. 2015; 9(4): 568–575.
    CrossRefPubMed
  62. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160): 703–713.
    PubMed
  63. Scott R, O'Brien R, Fulcher G, et al. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009; 32(3): 493–498.
    CrossRefPubMed
  64. Ginsberg HN, Elam MB, Lovato LC, et al. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17): 1563–1574.
    CrossRefPubMed
  65. Stanowisko Polskiego Towarzystwa Diabetologicznego „Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2016” . Diabetol Klin. 2016; 5(supl. A): A1–A76.
  66. Li W, Yanoff M, Liu X, et al. Retinal capillary pericyte apoptosis in early human diabetic retinopathy. Chin Med J (Engl). 1997; 110(9): 659–663.
    PubMed
  67. Ejaz S, Chekarova I, Ejaz A, et al. Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab. 2008; 10(1): 53–63.
    CrossRefPubMed
  68. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012; 12(4): 346–354.
    CrossRefPubMed
  69. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007; 14(4): 179–183.
    CrossRefPubMed
  70. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999; 48(5): 643–648.
    PubMed
  71. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329(14): 977–986.
    CrossRefPubMed
  72. Schrier RW, Estacio RO, Mehler PS, et al. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol. 2007; 3(8): 428–438.
    CrossRefPubMed
  73. Bosomworth NJ. Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. Can Fam Physician. 2013; 59(11): 1169–1180.
    PubMed
  74. Chew EY, Ambrosius WT, Davis MD, et al. ACCORD Study Group, ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010; 363(3): 233–244.
    CrossRefPubMed
  75. Noonan JE, Jenkins AJ, Ma JX, et al. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013; 62(12): 3968–3975.
    CrossRefPubMed
  76. Stanowisko Polskiego Towarzystwa Diabetologicznego „Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2016”. Diabetol Klin. 2016; 5(supl. A): A1–A76.
  77. Rydén L, Grant PJ, Anker SD, et al. Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), Document Reviewers. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013; 34(39): 3035–3087.
    CrossRefPubMed
  78. Wożakowska-Kapłon B, Filipiak K, Mamcarz A, et al. [Actual problems of dyslipidaemia treatment in Poland - 2nd Declaration of Sopot. Experts' Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy]. [Article in Polish]. Kardiol Pol. 2014; 72(9): 847–853.
    CrossRefPubMed
  79. Aguiar C, Alegria E, Bonadonna RC, et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atheroscler Suppl. 2015; 19: 1–12.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Folia Cardiologica

O Via Medica Reklama
Księgarnia (Ikamed) TVMed
Aktualności
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice